231 related articles for article (PubMed ID: 26966698)
1. Construction of a hybrid β-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivo.
Tropak MB; Yonekawa S; Karumuthil-Melethil S; Thompson P; Wakarchuk W; Gray SJ; Walia JS; Mark BL; Mahuran D
Mol Ther Methods Clin Dev; 2016; 3():15057. PubMed ID: 26966698
[TBL] [Abstract][Full Text] [Related]
2. In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.
Sinici I; Yonekawa S; Tkachyova I; Gray SJ; Samulski RJ; Wakarchuk W; Mark BL; Mahuran DJ
PLoS One; 2013; 8(3):e57908. PubMed ID: 23483939
[TBL] [Abstract][Full Text] [Related]
3. Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff Mice.
Osmon KJ; Woodley E; Thompson P; Ong K; Karumuthil-Melethil S; Keimel JG; Mark BL; Mahuran D; Gray SJ; Walia JS
Hum Gene Ther; 2016 Jul; 27(7):497-508. PubMed ID: 27199088
[TBL] [Abstract][Full Text] [Related]
4. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
[TBL] [Abstract][Full Text] [Related]
5. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
[TBL] [Abstract][Full Text] [Related]
6. Increased phosphorylation of HexM improves lysosomal uptake and potential for managing GM2 gangliosidoses.
Benzie G; Bouma K; Battellino T; Cooper S; Hemming R; Kammouni W; Liu L; Do C; Khajehpour M; Perreault H; Kornfeld S; Triggs-Raine B; Mark BL
BBA Adv; 2022; 2():100032. PubMed ID: 37082581
[TBL] [Abstract][Full Text] [Related]
7. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
[TBL] [Abstract][Full Text] [Related]
8. A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.
Hou Y; McInnes B; Hinek A; Karpati G; Mahuran D
J Biol Chem; 1998 Aug; 273(33):21386-92. PubMed ID: 9694901
[TBL] [Abstract][Full Text] [Related]
9. Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts.
Kitakaze K; Tasaki C; Tajima Y; Hirokawa T; Tsuji D; Sakuraba H; Itoh K
Biochem Biophys Rep; 2016 Sep; 7():157-163. PubMed ID: 28955902
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis.
Matsuoka K; Tamura T; Tsuji D; Dohzono Y; Kitakaze K; Ohno K; Saito S; Sakuraba H; Itoh K
Mol Ther; 2011 Jun; 19(6):1017-24. PubMed ID: 21487393
[TBL] [Abstract][Full Text] [Related]
11. Novel bicistronic lentiviral vectors correct β-Hexosaminidase deficiency in neural and hematopoietic stem cells and progeny: implications for in vivo and ex vivo gene therapy of GM2 gangliosidosis.
Ornaghi F; Sala D; Tedeschi F; Maffia MC; Bazzucchi M; Morena F; Valsecchi M; Aureli M; Martino S; Gritti A
Neurobiol Dis; 2020 Feb; 134():104667. PubMed ID: 31682993
[TBL] [Abstract][Full Text] [Related]
12. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
13. Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.
Liu Y; Hoffmann A; Grinberg A; Westphal H; McDonald MP; Miller KM; Crawley JN; Sandhoff K; Suzuki K; Proia RL
Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8138-43. PubMed ID: 9223328
[TBL] [Abstract][Full Text] [Related]
14. Investigating Immune Responses to the scAAV9-
Kot S; Karumuthil-Melethil S; Woodley E; Zaric V; Thompson P; Chen Z; Lykken E; Keimel JG; Kaemmerer WF; Gray SJ; Walia JS
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201771
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
16. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
Gort L; de Olano N; Macías-Vidal J; Coll MA;
Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
[TBL] [Abstract][Full Text] [Related]
17. Promoters for the human beta-hexosaminidase genes, HEXA and HEXB.
Norflus F; Yamanaka S; Proia RL
DNA Cell Biol; 1996 Feb; 15(2):89-97. PubMed ID: 8634145
[TBL] [Abstract][Full Text] [Related]
18. Functionality of a bicistronic construction containing
Shaimardanova AA; Chulpanova DS; Solovyeva VV; Aimaletdinov AM; Rizvanov AA
Neural Regen Res; 2022 Jan; 17(1):122-129. PubMed ID: 34100447
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate active site residues in lysosomal beta-hexosaminidase A.
Fernandes MJ; Yew S; Leclerc D; Henrissat B; Vorgias CE; Gravel RA; Hechtman P; Kaplan F
J Biol Chem; 1997 Jan; 272(2):814-20. PubMed ID: 8995368
[TBL] [Abstract][Full Text] [Related]
20. Identification of an active acidic residue in the catalytic site of beta-hexosaminidase.
Tse R; Vavougios G; Hou Y; Mahuran DJ
Biochemistry; 1996 Jun; 35(23):7599-607. PubMed ID: 8652542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
